Table 5. AML patient characteristics.
| AML patient characteristics | Total N = 226 |
|---|---|
| Gender | |
| Male | 124 (54.86%) |
| Female | 102 (45.13%) |
| Age at diagnosis, mean (range) | 57.7 (18–81) |
| FLT3 status | |
| FLT3 wild type | 160 (70.79%) |
| FLT3 mutated | 61 (26.99%) |
| Not determined | 5 (2.21%) |
| NPM1 status | |
| NPM1 wild type | 147 (65.04%) |
| NPM1 mutated | 72 (31.85%) |
| Not determined | 7 (12.04%) |
| CEBPA status | |
| Monoallelic | 29 (12.83%) |
| Biallelic | 2 (0.88%) |
| Karyotype | |
| Normal Karyotype | 169 (74.77%) |
| NK-low risk | 31 (13.71%) |
| NK-intermediate risk | 121 (53.53%) |
| NK-high risk | 17 (7.52%) |
| Aberrant Karyotype: | 43 (19.02%) |
| Aberrant -low risk | 5 (2.21%) |
| Aberrant -intermediate risk | 21 (9.29%) |
| Aberrant -high risk | 17 (7.52%) |
| Not determined | 14 (6.19%) |
| Treatmenta | |
| Dnr + AraC | 163 (72.12%) |
| Ida + AraC | 20 (8.85%) |
| Ida + AraC + CdA | 15 (6.63%) |
| AraC | 10 (4.42%) |
| Dnr + AraC + 6-TG | 4 (1.76%) |
| Dnr + mylotarg | 2 (0.88%) |
| Dnr + AraC + Mitox | 2 (0.88%) |
| Others | 10 (4.42%) |
| Treatment responseb | |
| CR | 167 (73.89%) |
| Non-CR | 32 (11.16%) |
| Not evaluated | 27 (11.94%) |
a
Dnr = Daunorubicine; AraC = Cytarabine; 6-TG = 6-thioguanine; Ida = Idarubicine; Cda = Cladribine; Mitox = Mitoxantrone; mylotarg = Gemtuzumab ozogamicin
b
CR = complete remission